Abbott‘s (NYSE:ABT) bioresorbable scaffold has been plagued with a myriad of troubling data, including a study that showed that the device is associated with an increase in thrombosis and target lesion failure. In April, Abbott pulled the stent from European markets.
In response to widespread criticism of the technology, the EuroPCR team released a statement this week defending bioresorbable stents as “an important option to optimise outcomes in patients whose needs are not adequately met with current devices.”
Get the full story at our sister site, Drug Delivery Business News.
The post EuroPCR Roundup: Bioresorbable stents show promise, but metallic drug-eluting stents remain standard appeared first on MassDevice.
from MassDevice http://ift.tt/2rIZKsu
Cap comentari:
Publica un comentari a l'entrada